CSL Dispatches First Australian Made Doses of AstraZeneca COVID-19 Vaccine

CSL

Melbourne, 24 March 2021 – CSL Limited (ASX:CSL) has released 830,000 locally made doses of the AstraZeneca COVID-19 vaccine, ahead of initial scheduling.

The release follows the completion of the final stages of manufacture – known as fill and finish – and extensive quality checks at Seqirus’ vaccine facilities in Parkville, Melbourne.

There are a further 2.5 million doses in cold storage, undergoing the final stages of testing, approval and release, which will be distributed in the coming weeks. The manufacturing process is ongoing and CSL expects to release an average of a million doses a week over the course of the campaign, subject to regulatory approvals.

Manufacture of the first batch commenced in November at CSL Behring in Broadmeadows with the thaw of a vial of ‘starter material’. Since then, CSL employees have worked at pace to grow the vaccine in 2000 litre bioreactors, before harvesting the bulk drug substance and filtering it into a concentrate, ready for the final stages of filling into vials.

At every stage of the manufacturing process, the vaccine has undergone extensive checks – and no vaccine is released until the Therapeutics Goods Administration, AstraZeneca and CSL confirm the potency and safety of the locally made product.

In addition to rigorous analytical tests on each batch by CSL and the TGA, every individual vial has been visually inspected by a skilled operator to ensure it is fully compliant with safety and quality standards before it is released to the public.

/Public Release. This material comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length.